Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography, Three-Dimensional | 6 | 2014 | 66 | 1.120 |
Why?
|
| Anthracyclines | 7 | 2013 | 331 | 0.890 |
Why?
|
| Heart Neoplasms | 3 | 2010 | 214 | 0.800 |
Why?
|
| Echocardiography | 14 | 2014 | 1182 | 0.670 |
Why?
|
| Cardiomyopathies | 3 | 2014 | 610 | 0.670 |
Why?
|
| Multimodal Imaging | 3 | 2018 | 550 | 0.660 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 46 | 0.640 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2010 | 303 | 0.610 |
Why?
|
| Cardiovascular System | 1 | 2018 | 145 | 0.580 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2014 | 435 | 0.570 |
Why?
|
| Cardiovascular Diseases | 4 | 2018 | 2195 | 0.530 |
Why?
|
| Radiation Injuries | 3 | 2018 | 1411 | 0.510 |
Why?
|
| Heart Ventricles | 4 | 2014 | 846 | 0.510 |
Why?
|
| Antineoplastic Agents | 12 | 2020 | 14289 | 0.500 |
Why?
|
| Echocardiography, Doppler | 2 | 2014 | 180 | 0.480 |
Why?
|
| Ventricular Function | 1 | 2014 | 93 | 0.460 |
Why?
|
| Early Diagnosis | 2 | 2014 | 298 | 0.460 |
Why?
|
| Heart Diseases | 4 | 2012 | 732 | 0.440 |
Why?
|
| Ventricular Function, Left | 6 | 2014 | 603 | 0.430 |
Why?
|
| Neoplasms | 14 | 2020 | 15193 | 0.420 |
Why?
|
| Fluorocarbons | 2 | 2012 | 63 | 0.410 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2012 | 112 | 0.410 |
Why?
|
| Amyloidosis | 1 | 2012 | 176 | 0.370 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 726 | 0.360 |
Why?
|
| Radiotherapy | 4 | 2020 | 1824 | 0.340 |
Why?
|
| Cardiac Tamponade | 1 | 2009 | 51 | 0.330 |
Why?
|
| Cardiotoxicity | 2 | 2020 | 155 | 0.320 |
Why?
|
| Endocardium | 1 | 2008 | 50 | 0.320 |
Why?
|
| Echocardiography, Stress | 1 | 2008 | 24 | 0.320 |
Why?
|
| Warfarin | 1 | 2009 | 152 | 0.310 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2013 | 592 | 0.300 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 435 | 0.290 |
Why?
|
| Predictive Value of Tests | 7 | 2018 | 4892 | 0.280 |
Why?
|
| Lymphoma | 1 | 2013 | 1467 | 0.250 |
Why?
|
| Leukemia | 1 | 2013 | 1635 | 0.250 |
Why?
|
| Pericarditis, Constrictive | 1 | 2003 | 11 | 0.240 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 50 | 0.230 |
Why?
|
| Anticoagulants | 1 | 2009 | 787 | 0.220 |
Why?
|
| Heart | 3 | 2013 | 1223 | 0.210 |
Why?
|
| Contrast Media | 2 | 2012 | 1472 | 0.210 |
Why?
|
| Troponin I | 2 | 2013 | 127 | 0.210 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 1648 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2013 | 3251 | 0.200 |
Why?
|
| Hemangiosarcoma | 1 | 2003 | 234 | 0.190 |
Why?
|
| Arteriosclerosis | 1 | 2001 | 185 | 0.190 |
Why?
|
| Endocarditis | 2 | 2013 | 125 | 0.180 |
Why?
|
| Breast Neoplasms | 8 | 2013 | 15694 | 0.180 |
Why?
|
| Hypolipidemic Agents | 1 | 2001 | 190 | 0.180 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 1011 | 0.180 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2012 | 171 | 0.180 |
Why?
|
| Ohio | 3 | 2014 | 113 | 0.170 |
Why?
|
| Risk Assessment | 6 | 2020 | 6869 | 0.160 |
Why?
|
| Reproducibility of Results | 6 | 2014 | 6009 | 0.160 |
Why?
|
| Trastuzumab | 7 | 2013 | 696 | 0.160 |
Why?
|
| Stroke Volume | 4 | 2014 | 577 | 0.160 |
Why?
|
| Coronary Disease | 1 | 2001 | 764 | 0.150 |
Why?
|
| Sensitivity and Specificity | 5 | 2012 | 4971 | 0.150 |
Why?
|
| Heart Failure | 4 | 2013 | 2516 | 0.150 |
Why?
|
| Humans | 38 | 2020 | 261506 | 0.140 |
Why?
|
| Ultrasonography | 3 | 2012 | 1863 | 0.140 |
Why?
|
| Cardiotonic Agents | 2 | 2013 | 151 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 524 | 0.130 |
Why?
|
| Risk Factors | 6 | 2020 | 17523 | 0.120 |
Why?
|
| Female | 26 | 2014 | 141928 | 0.120 |
Why?
|
| Snakes | 1 | 2013 | 7 | 0.120 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 4744 | 0.110 |
Why?
|
| Peroxidase | 1 | 2013 | 132 | 0.110 |
Why?
|
| Bites and Stings | 1 | 2013 | 44 | 0.110 |
Why?
|
| Middle Aged | 22 | 2014 | 86204 | 0.110 |
Why?
|
| Electrocardiography | 3 | 2013 | 1145 | 0.100 |
Why?
|
| Chest Pain | 1 | 2013 | 155 | 0.100 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 311 | 0.100 |
Why?
|
| Aneurysm, False | 1 | 2013 | 153 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2009 | 5319 | 0.100 |
Why?
|
| Biomechanical Phenomena | 1 | 2012 | 338 | 0.100 |
Why?
|
| Male | 18 | 2014 | 123000 | 0.100 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2012 | 343 | 0.100 |
Why?
|
| Observer Variation | 1 | 2012 | 671 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 323 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 248 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 703 | 0.090 |
Why?
|
| Hemodynamics | 3 | 2011 | 935 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2011 | 333 | 0.090 |
Why?
|
| Heart Valve Diseases | 1 | 2011 | 193 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 3441 | 0.080 |
Why?
|
| Aged | 12 | 2013 | 70117 | 0.080 |
Why?
|
| Image Enhancement | 2 | 2011 | 561 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 4298 | 0.080 |
Why?
|
| Pericardial Effusion | 1 | 2009 | 118 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 15862 | 0.070 |
Why?
|
| Adult | 13 | 2013 | 77950 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2013 | 12873 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 297 | 0.070 |
Why?
|
| Equipment Design | 1 | 2010 | 1204 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2011 | 462 | 0.070 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 460 | 0.070 |
Why?
|
| Prognosis | 4 | 2018 | 21713 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2010 | 829 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2008 | 598 | 0.060 |
Why?
|
| Taxoids | 3 | 2013 | 967 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 849 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2012 | 29902 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2010 | 600 | 0.060 |
Why?
|
| Biopsy | 1 | 2012 | 3443 | 0.060 |
Why?
|
| Exercise Test | 1 | 2005 | 312 | 0.060 |
Why?
|
| Pyrroles | 1 | 2008 | 576 | 0.060 |
Why?
|
| Rats | 1 | 2013 | 6086 | 0.060 |
Why?
|
| Mitral Valve | 1 | 2005 | 271 | 0.060 |
Why?
|
| Systole | 2 | 2014 | 196 | 0.060 |
Why?
|
| Thrombosis | 1 | 2010 | 781 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1162 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2012 | 6100 | 0.050 |
Why?
|
| Indoles | 1 | 2008 | 1009 | 0.050 |
Why?
|
| Patient Selection | 1 | 2010 | 2055 | 0.050 |
Why?
|
| Dyspnea | 1 | 2005 | 416 | 0.050 |
Why?
|
| Time Factors | 3 | 2013 | 12926 | 0.050 |
Why?
|
| Diastole | 2 | 2012 | 187 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2013 | 726 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2005 | 386 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2009 | 3981 | 0.050 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2001 | 88 | 0.050 |
Why?
|
| Texas | 2 | 2011 | 6311 | 0.050 |
Why?
|
| Piperazines | 1 | 2010 | 2101 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2001 | 253 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2010 | 1237 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 1374 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 980 | 0.050 |
Why?
|
| Algorithms | 1 | 2011 | 3890 | 0.050 |
Why?
|
| Blood Coagulation | 1 | 2001 | 185 | 0.050 |
Why?
|
| Young Adult | 4 | 2012 | 21445 | 0.050 |
Why?
|
| Cardiac Catheterization | 3 | 2011 | 687 | 0.040 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2001 | 192 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 235 | 0.040 |
Why?
|
| Ethanol | 1 | 2001 | 264 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 7702 | 0.040 |
Why?
|
| Risk | 2 | 2013 | 1972 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 259 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 2307 | 0.040 |
Why?
|
| Cholesterol | 1 | 2001 | 658 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 4367 | 0.040 |
Why?
|
| Incidence | 3 | 2014 | 5673 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2010 | 3518 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 891 | 0.040 |
Why?
|
| Acute Disease | 1 | 2001 | 2422 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 14889 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2013 | 3005 | 0.030 |
Why?
|
| Comorbidity | 2 | 2013 | 2352 | 0.030 |
Why?
|
| Prevalence | 2 | 2011 | 3260 | 0.030 |
Why?
|
| Pets | 1 | 2013 | 21 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2001 | 2594 | 0.030 |
Why?
|
| Microbubbles | 1 | 2012 | 14 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2012 | 37 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 4757 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 30 | 0.030 |
Why?
|
| Genes, erbB-2 | 1 | 2013 | 229 | 0.030 |
Why?
|
| Cardiotoxins | 1 | 2011 | 14 | 0.030 |
Why?
|
| North America | 1 | 2012 | 314 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 649 | 0.030 |
Why?
|
| Inflammation | 1 | 2001 | 2522 | 0.020 |
Why?
|
| Biomarkers | 2 | 2013 | 5047 | 0.020 |
Why?
|
| Troponin C | 1 | 2011 | 23 | 0.020 |
Why?
|
| Albumins | 1 | 2012 | 258 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 291 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2013 | 9244 | 0.020 |
Why?
|
| Latin America | 1 | 2011 | 115 | 0.020 |
Why?
|
| Brazil | 1 | 2011 | 165 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 1085 | 0.020 |
Why?
|
| Propensity Score | 1 | 2013 | 750 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1323 | 0.020 |
Why?
|
| Consensus | 1 | 2013 | 978 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2014 | 37905 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 862 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 2231 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.020 |
Why?
|
| Sepsis | 1 | 2013 | 652 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 2292 | 0.020 |
Why?
|
| Animals | 3 | 2013 | 59536 | 0.020 |
Why?
|
| Survivors | 1 | 2012 | 1031 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 1271 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 1996 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 3001 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 1665 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 4938 | 0.020 |
Why?
|
| Cardiology | 1 | 2011 | 530 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2011 | 1335 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 1832 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2013 | 32848 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 764 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2011 | 851 | 0.020 |
Why?
|
| Registries | 1 | 2011 | 2170 | 0.010 |
Why?
|
| Mass Screening | 1 | 2012 | 1509 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 4988 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8865 | 0.010 |
Why?
|
| Dobutamine | 1 | 2001 | 54 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2001 | 73 | 0.010 |
Why?
|
| Heart Septum | 1 | 2001 | 54 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2001 | 164 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 5637 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 3719 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2008 | 1756 | 0.010 |
Why?
|
| Survival Rate | 1 | 2014 | 12221 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 866 | 0.010 |
Why?
|
| United States | 1 | 2013 | 15433 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 4320 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 31252 | 0.010 |
Why?
|